Across TCGA pan-cancer cohorts, HOXC6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HOXC6 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher HOXC6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HOXC6 expression acts as an unfavorable survival marker.

OV, UCEC, and LIHC are the cancer types where HOXC6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.240	0.541	.041	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	II,III,IV	0.152	0.614	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HOXC6 tumor-vs-normal RNA expression · all HOXC6 data types